ESC Premium Access

Discussion - How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation.

Topic: Inflammation and microcirculation
Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by unrestricted educational grants from Novartis and Amgen

Congress Presentation

About the speakers

Professor Peter Libby

Brigham and Women's Hospital, Boston (United States of America)
35 presentations

Professor John Eric Deanfield

University College London, London (United Kingdom of Great Britain & Northern Ireland)
50 presentations

4 more presentations in this session

Introduction - The post ACS patient and residual risk.

Speaker: Professor P. Libby (Boston, US)


Inflammation as potential target for therapy to target residual risk post ACS.

Speaker: Doctor P. Ridker (Boston, US)


Beyond statins: the role of ezetimibe in targeting residual risk.

Speaker: Professor C. Packard (Glasgow, GB)


Novel strategies targeting residual risk: the promise of PCSK9 inhibiting therapies.

Speaker: Professor E. Stroes (Amsterdam, NL)


Access the full session

How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation

Speakers: Professor P. Libby, Professor J. Deanfield, Professor P. Libby, Doctor P. Ridker, Professor C. Packard...

About the event


ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb